The National Institute of Neurological Disorders and Stroke, part of the National Institutes of Health, is looking for individuals to participate in clinical studies. Participating in clinical trials allows you to play an active role in research on the nature and causes of many disorders of the brain and nervous system, and to possibly help physician-scientists develop future treatments. The information below is designed to help you quickly learn about actively recruiting research studies for which you or someone you know may be eligible.
The purpose of the Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage III (CLEAR III) trial is to determine the benefit of using the clot-busting drug recombinant tissue plasminogen activator (t-PA) in conjunction with clot removal for the treatment of intraventricular hemorrhage (IVH). IVH is sudden bleeding into the ventricular system of the brain, often the result of severe intracerebral hemorrhage (ICH).
The trial will compare extraventricular draining plus t-PA with extraventricular draining plus placebo (an inactive substance) in managing and treating individuals with small ICH and large IVH. Extraventricular draining involves surgically inserting tubes that drain fluid from the brain’s ventricles.
Approximately 500 participants will be enrolled in the trial. Participants will receive either t-PA or a placebo every 8 hours for up to 12 doses. Symptom onset must be within 24 hours prior to a diagnostic computed tomography (CT) scan. The neurological function of the 2 groups will be compared at multiple time points over the course of a year following treatment. Patient neurological status at 6 months is the primary outcome measurement.
Contact: Karen Lane; telephone: 410-614-3461; email:firstname.lastname@example.org; or the Brain Injury Outcomes main office: 410-614-6996
Last Reviewed November 9, 2012